BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38212213)

  • 21. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
    Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M
    Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer and Its Relationship with Demographic-Histopathologic Risk Factors and
    Araz M; Soydal Ç; Özkan E; Akkuş P; Nak D; Küçük NÖ; Kır KM
    Cancer Biother Radiopharm; 2021 Jun; 36(5):425-432. PubMed ID: 32379488
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
    Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
    Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
    Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
    Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of PET/Computed Tomography in Elderly Thyroid Cancer: Tumor Biology and Clinical Management.
    Sonavane SN; Basu S
    PET Clin; 2023 Jan; 18(1):81-101. PubMed ID: 36718717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
    Lee JW; Lee SM; Lee DH; Kim YJ
    J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 68Ga-FAPI PET/CT in Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy.
    Fu H; Fu J; Huang J; Su X; Chen H
    Clin Nucl Med; 2021 May; 46(5):427-430. PubMed ID: 33661204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer.
    Iwano S; Kato K; Ito S; Tsuchiya K; Naganawa S
    Ann Nucl Med; 2012 Apr; 26(3):207-13. PubMed ID: 22160654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT.
    Verma P; Malhotra G; Meshram V; Chandak A; Sonavane S; Lila AR; Bandgar TR; Asopa RV
    Clin Nucl Med; 2021 Aug; 46(8):e406-e409. PubMed ID: 33883490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of simultaneous
    Klain M; Nappi C; Nicolai E; Romeo V; Piscopo L; Giordano A; Gaudieri V; Zampella E; Pace L; Carlo C; Salvatore M; Schlumberger M; Cuocolo A
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3066-3073. PubMed ID: 32601803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDG PET/CT in differentiated thyroid cancer patients with low thyroglobulin levels.
    Lebbink CA; de Vries LH; Borel Rinkes IHM; Braat AJAT; van Leeuwaarde RS; Lodewijk L; van Treijen MJC; Vriens MR; Valk GD; van Santen HM; de Keizer B
    Eur J Endocrinol; 2022 May; 187(1):101-110. PubMed ID: 35521710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms.
    Adnan A; Raju S; Kumar R; Basu S
    PET Clin; 2022 Jul; 17(3):343-367. PubMed ID: 35717097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal threshold of stimulated serum thyroglobulin level for
    Chai H; Zhang H; Yu YL; Gao YC
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):429-432. PubMed ID: 28585147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions.
    Kelders A; Kennes LN; Krohn T; Behrendt FF; Mottaghy FM; Verburg FA
    Nucl Med Commun; 2014 Feb; 35(2):176-81. PubMed ID: 24201550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Head-to-head comparison of [
    Ballal S; Yadav MP; Roesch F; Satapathy S; Moon ES; Martin M; Wakade N; Sheokand P; Tripathi M; Chandekar KR; Agarwal S; Sahoo RK; Rastogi S; Bal C
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):233-244. PubMed ID: 37642703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview.
    Treglia G; Muoio B; Giovanella L; Salvatori M
    Eur Arch Otorhinolaryngol; 2013 May; 270(6):1783-7. PubMed ID: 23053387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of 68 Ga-NODAGA-RGD PET-CT in patients of carcinoma thyroid with thyroglobulin elevated negative radioiodine scintigraphy (TENIS) with a head-to-head comparison with FDG-PET/CT.
    Gondhane A; Verma P; Chandak A; Basu S
    Nucl Med Commun; 2024 May; 45(5):412-419. PubMed ID: 38445350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.